AMAG Pharma Appoints Rainier’s Myers to Succeed CEO William Heiden

AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]) on Tuesday announced Scott Myers has been appointed its new CEO. Myers was most recently CEO of bladder cancer drug developer Rainier Therapeutics. Previously he served as CEO of Cascadian Therapeutics, which was acquired by Seattle Genetics (NASDAQ: [[ticker:SGEN]]) in 2018. He also spent time as CEO of medical device company Aerocrine AB.

At AMAG, Myers succeeds William Heiden, who has served as CEO of the Waltham, MA company for eight years. AMAG announced in January that Heiden would be leaving, as well as plans to divest its two commercialized women’s health products.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.